-- 阿联酋将于周五退出石油输出国组织(欧佩克)。Rystad Energy公司表示,此举将削弱该组织的结构性力量。 阿联酋已加入欧佩克超过五十年。 据阿联酋通讯社报道,阿联酋此举增强了其“应对市场动态的灵活性,同时继续以审慎负责的方式为市场稳定做出贡献”。阿联酋能源和基础设施部长苏海尔·马兹鲁伊也在社交媒体平台X上分享了这篇文章。 受美国和以色列与伊朗战争的影响,石油市场面临广泛的供应中断。在美伊停火以及以色列和黎巴嫩随后达成停火协议后,冲突暂时停止。 阿联酋通讯社的文章指出,“这一决定体现了阿联酋的长期战略和经济愿景以及不断发展的能源结构,包括加快对国内能源生产的投资。” Rystad Energy在一份报告中指出,阿联酋是欧佩克成员国中少数几个拥有剩余产能的国家之一,沙特阿拉伯也位列其中。欧佩克采用产量配额制度来稳定全球石油市场。 Rystad地缘政治分析主管豪尔赫·莱昂写道:“因此,阿联酋的退出削弱了欧佩克管理市场能力的核心支柱之一。” 莱昂表示,随着阿联酋的退出,沙特阿拉伯将不得不承担更多稳定油价的重任。 莱昂指出:“鉴于霍尔木兹海峡持续动荡以及更广泛的地缘政治不确定性,短期影响可能较为有限,但长期影响更为深远。一个结构性削弱的欧佩克,其内部剩余产能减少,将越来越难以调节供应和稳定油价。”布伦特原油上涨2.4%,至每桶110.82美元;西德克萨斯中质原油上涨3.3%,至每桶99.56美元。
Related Articles
Sector Update: Tech Stocks Fall Late Afternoon
Tech stocks fell late Tuesday afternoon, with the State Street Technology Select Sector SPDR ETF (XLK) dropping 1.5% and the State Street SPDR S&P Semiconductor ETF (XSD) slumping 4.4%.The Philadelphia Semiconductor index shed 3.3%.In corporate news, OpenAI recently missed its own targets for new users and revenue, the Wall Street Journal reported late Monday, citing people familiar with the matter. Tech bellwether Nvidia (NVDA) fell 1.2%, Broadcom (AVGO) dropped 4.2%, Advanced Micro Devices (AMD) shed 3.1%, Oracle (ORCL) lost 3.6%, and Intel (INTC) declined 1.4%.Lam Research (LRCX), Applied Materials (AMAT) and KLA (KLAC) were among the chip equipment companies believed to have received a letter last week from the US Department of Commerce ordering them to halt certain tool shipments to China's second-largest chipmaker Hua Hong, Reuters reported. Lam declined 3%, Applied Materials dropped 5.1%, and KLA shed 4.1%.Amazon.com (AMZN) plans to make OpenAI's artificial intelligence models available to its customers after Microsoft (MSFT) relinquished its exclusive rights to resell the ChatGPT maker's products, Bloomberg reported Tuesday, citing Amazon Web Services CEO Matt Garman in a Bloomberg Television interview. Amazon shares were down 0.6%, and Microsoft rose 0.6%.Spotify Technology (SPOT) reported stronger-than-expected Q1 profit, but its premium subscriber growth and outlook disappointed investors. The stock fell 12%.
Research Alert: Paccar: Q1 Eps Match Expectations; Class-8 Outlook Reiterated
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PCAR's Q1 results matched consensus with operating EPS of $1.15 vs. $0.96 in the prior year, supported by the absence of litigation charges that impacted Q1 2025. New truck deliveries fell 7K units to 33.1K globally, with North American Class-8 shipments declining while Europe showed strength. The Parts business managed positive expansion despite truck sales softness, benefiting from strategic investments in distribution infrastructure. Management maintained an upbeat tone on customer demand trends, though their North American outlook for retail Class-8 truck sales remained unchanged from Q4. PCAR generated healthy operating cash flow of $972M vs. $910M and maintained a strong balance sheet, in our view. Management projected full-year capex of ~$750M and R&D expenses of ~$475M for next-generation powertrains. We see the unchanged shipment projections as a signal that management is not entirely confident an inflection is occurring stronger than previously anticipated.
Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data
Erasca (ERAS) shares fell 48% Tuesday after the company reported preliminary phase 1 dose-escalation data for its experimental ERAS-0015 in patients with RAS-mutant solid tumors, including colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma.The preliminary data, from ongoing trials in the US and China, suggest ERAS-0015 may be combined with standard-of-care doses of panitumumab, positioning it as a potential backbone therapy for future combination regimens, the company said.The therapy was generally "well tolerated," with no dose-limiting toxicities or treatment discontinuations due to adverse events, according to a statement.Erasca said it selected 24 mg and 32 mg once daily as recommended doses for further study and said the drug showed "promising clinical potential" for combination use with panitumumab.In a regulatory filing, the company said a patient, who was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma, had died. The company said grade 3 treatment-related adverse events of pneumonitis progressed to grade 5 following withdrawal of supportive care per patient decision.Price: $9.96, Change: $-9.20, Percent Change: -48.02%